Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Adaptimmune
Gilead Sciences
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Fred Hutchinson Cancer Center
Genocea Biosciences, Inc.
Fred Hutchinson Cancer Center
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bioven Sdn. Bhd.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
EMD Serono
Merck KGaA, Darmstadt, Germany
Bioven Sdn. Bhd.
Cancer Research UK